Medical News:Data Confirm PARP Inhibitor (Olaparib) Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

Medical News:Data Confirm PARP Inhibitor Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

Action Points

Note that this randomized, placebo controlled study demonstrates that olaparib, an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor, significantly improved progression-free survival but not overall survival, in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.